{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:54:58Z","timestamp":1783508098208,"version":"3.55.0"},"reference-count":47,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Programa Nacional de Apoio \u00e0 Aten\u00e7\u00e3o Oncol\u00f3gica","award":["NUP 25000.055356\/2015-04"],"award-info":[{"award-number":["NUP 25000.055356\/2015-04"]}]},{"name":"Associa\u00e7\u00e3o dos Amigos do Hospital de Cl\u00ednicas (AAHC)","award":["NUP 25000.055356\/2015-04"],"award-info":[{"award-number":["NUP 25000.055356\/2015-04"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Monitoring measurable residual disease (MRD) is critical for the management of B-cell acute lymphoblastic leukemia (B-ALL). While a quantitative assessment of BCR::ABL1 transcripts is standard for Philadelphia chromosome-positive cases (Ph+ ALL), a multiparameter flow cytometry (FCM) is commonly used for MRD detection in other genetic subtypes. A total of 106 B-ALL patients underwent genetic and phenotypic analyses. Among them, 27 patients (20 adults and 7 children) harbored the t(9;22)(q34.1;q11.2) translocation and\/or the BCR::ABL1 rearrangement. A high correlation between the BCR::ABL1 transcript levels (PCR-MRD) and a standardized FCM-based method for MRD detection (FCM-MRD) was observed (r = 0.7801, p &lt; 0.001), with a concordance rate of 88% (\u03ba = 0.761). The FCM detected MRD in 82.9% of the samples with transcript levels of &gt; 0.01%. The CD34+CD38\u2212\/dim blast pattern was significantly more frequent in Ph+ ALL (77.7%), compared to other B-ALL cases (20.2%, p &lt; 0.0001). Additionally, Ph+ ALL exhibited a higher expression of CD66c+\/CD73+ (94.0% vs. 56.9%), CD66c+\/CD304+ (58.8% vs. 6.9%), and CD73+\/CD304+ (75.5% vs. 15.5%) than the other B-ALL subtypes (p &lt; 0.001). In conclusion, this high-sensitivity FCM-MRD demonstrated comparable performance to the PCR-MRD, serving as a complementary tool for MRD assessment in Ph+ ALL. Moreover, a distinct leukemia-associated immunophenotype was identified, highlighting potential biomarkers for MRD monitoring.<\/jats:p>","DOI":"10.3390\/ijms26052116","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T02:48:37Z","timestamp":1740710917000},"page":"2116","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comprehensive Analysis of High-Sensitive Flow Cytometry and Molecular Mensurable Residual Disease in Philadelphia Chromosome-Positive Acute Leukemia"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9884-4735","authenticated-orcid":false,"given":"Ana Paula","family":"de Azambuja","sequence":"first","affiliation":[{"name":"Hospital de Cl\u00ednicas, Universidade Federal do Paran\u00e1, Curitiba 80060-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Lucia Vieira","family":"Mion","sequence":"additional","affiliation":[{"name":"Hospital de Cl\u00ednicas, Universidade Federal do Paran\u00e1, Curitiba 80060-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara Carolina","family":"Schluga","sequence":"additional","affiliation":[{"name":"Hospital de Cl\u00ednicas, Universidade Federal do Paran\u00e1, Curitiba 80060-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0148-998X","authenticated-orcid":false,"given":"Miriam Perlingeiro","family":"Beltrame","sequence":"additional","affiliation":[{"name":"Hospital de Cl\u00ednicas, Universidade Federal do Paran\u00e1, Curitiba 80060-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8052-6357","authenticated-orcid":false,"given":"Alexandra Cristina","family":"Senegaglia","sequence":"additional","affiliation":[{"name":"Hospital de Cl\u00ednicas, Universidade Federal do Paran\u00e1, Curitiba 80060-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2122-7277","authenticated-orcid":false,"given":"Vaneuza Araujo Moreira","family":"Funke","sequence":"additional","affiliation":[{"name":"Hospital de Cl\u00ednicas, Universidade Federal do Paran\u00e1, Curitiba 80060-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmem","family":"Bonfim","sequence":"additional","affiliation":[{"name":"Hospital de Cl\u00ednicas, Universidade Federal do Paran\u00e1, Curitiba 80060-900, Brazil"},{"name":"Duke Children\u2019s Hospital, Durham, NC 27710, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Pasquini","sequence":"additional","affiliation":[{"name":"Hospital de Cl\u00ednicas, Universidade Federal do Paran\u00e1, Curitiba 80060-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMra2113347","article-title":"Philadelphia Chromosome\u2013Positive Acute Lymphoblastic Leukemia","volume":"386","author":"Chiaretti","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.leukres.2017.01.034","article-title":"Genomic analysis of adult B-ALL identifies potential markers of shorter survival","volume":"56","author":"Patel","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood.2023020794","article-title":"Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel","volume":"143","author":"Boissel","year":"2024","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","article-title":"Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate","volume":"103","author":"DThomas","year":"2004","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1182\/blood-2008-04-148791","article-title":"BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome positive leukemias","volume":"112","author":"Jones","year":"2008","journal-title":"Blood"},{"key":"ref_6","first-page":"1536","article-title":"Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: A prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis","volume":"99","author":"Bartram","year":"2002","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1182\/blood-2009-02-204693","article-title":"Chronic myeloid leukemia (CML) with P190BCR-ABL: Analysis of characteristics, outcomes, and prognostic significance","volume":"114","author":"Verma","year":"2009","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1038\/bcj.2017.62","article-title":"Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia","volume":"7","author":"Gong","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1182\/blood-2019-126584","article-title":"BCR-ABL1 p190 in CML: A Minor Breakpoint with a Major Impact","volume":"134","author":"Awad","year":"2019","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-022-00265-2","article-title":"Distinct outcomes, ABL1 mutation profile, and transcriptome features between p190 and p210 transcripts in adult Philadelphia-positive acute lymphoblastic leukemia in the TKI era","volume":"11","author":"Shi","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1038\/s41375-022-01668-0","article-title":"Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: Different significance in typical ALL and in CML-like disease","volume":"36","author":"Zuna","year":"2022","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/s41588-023-01429-4","article-title":"Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia","volume":"55","author":"Kim","year":"2023","journal-title":"Nat. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-024-02053-4","article-title":"Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: Analysis of 971 patients","volume":"23","author":"Hovorkova","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1182\/blood-2012-06-379040","article-title":"Has MRD monitoring superseded other prognostic factors in adult ALL?","volume":"120","author":"Bruggemann","year":"2012","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/ajh.26993","article-title":"Minimal residual disease in Philadelphia-positive acute lymphoblastic leukemia: Maximizing the clinical yield of testing","volume":"98","author":"Saliba","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.bbmt.2018.03.015","article-title":"Comparative Analysis of Flow Cytometry and RQ-PCR for the Detection of Minimal Residual Disease in Philadelphia Chromosome\u2013Positive Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation","volume":"24","author":"Zhao","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.bbmt.2019.07.037","article-title":"Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplant","volume":"25","author":"Candoni","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Darzentas, F., Szczepanowski, M., Kotrov\u00e1, M., Hartmann, A., Beder, T., G\u00f6kbuget, N., Schwartz, S., Bastian, L., Baldus, C.D., and P\u00e1l, K. (2023). Insights into IGH clonal evolution in BCP-ALL: Frequency, mechanisms, associations, and diagnostic implications. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1125017"},{"key":"ref_19","first-page":"135","article-title":"TaqMan reverse transcriptase-polymerase chain reaction coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type","volume":"335","author":"Luthra","year":"2006","journal-title":"Methods Mol. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/annonc\/mdf156","article-title":"Quantitative measurement of BCR\/abl transcripts using real-time polymerase chain reaction","volume":"13","author":"Lee","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jfma.2016.12.002","article-title":"Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes","volume":"116","author":"Huang","year":"2017","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/sj.leu.2403348","article-title":"Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia","volume":"18","author":"Neale","year":"2004","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/08880018.2019.1636168","article-title":"Comparison between flow cytometry and standard PCR in the evaluation of MRD in children with acute lymphoblastic leukemia treated with the GBTLI LLA\u20142009 protocol","volume":"36","author":"Rocha","year":"2019","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia","volume":"129","author":"Theunissen","year":"2017","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Verbeek, M.W.C., and van der Velden, V.H.J. (2024). The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25094881"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/cyto.b.22043","article-title":"Correlation between a 10-color flow cytometric measurable residual disease analysis (MRD) and molecular MRD in adult acute lymphoblastic leukemia","volume":"102","author":"Singh","year":"2022","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/cyto.b.21831","article-title":"A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia\/Lymphoma Can Easily Achieve the Sensitivity of 2-in-106 and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 Patients","volume":"98","author":"Tembhare","year":"2020","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cyto.b.22120","article-title":"Highly sensitive single tube B-lymphoblastic leukemia\/lymphoma minimal\/measurable residual disease test robust to surface antigen directed therapy","volume":"104","author":"Gao","year":"2023","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"112429","DOI":"10.1016\/j.jim.2018.03.005","article-title":"Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia","volume":"475","author":"Theunissen","year":"2019","journal-title":"J. Immunol. Methods"},{"key":"ref_30","unstructured":"Euroflow Consortium (2024, November 24). EuroFlow Standard Operating Procedure (SOP) for Bulk Lysis for MRD Panels. Standardized EuroFlow Protocols, Available online: www.euroflow.org."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.1993.tb03026.x","article-title":"Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: Correlations with acute graft-versus-host disease and relapse","volume":"84","author":"Cross","year":"1993","journal-title":"Br. J. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/bjh.18499","article-title":"Multicentric standardization of minimal\/measurable residual disease in B-cell precursor acute lymphoblastic leukemia using next-generation flow cytometry in a low\/middle-level income country","volume":"200","author":"Bertolucci","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/ejh.13375","article-title":"Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"104","author":"Dombret","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/jama.2024.4783","article-title":"Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"331","author":"Jabbour","year":"2024","journal-title":"JAMA"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kulis, J., S\u0119dek, \u0141., S\u0142ota, \u0141., Perkowski, B., and Szczepa\u0144ski, T. (2022). Commonly Assessed Markers in Childhood BCP-ALL Diagnostic Panels and Their Association with Genetic Aberrations and Outcome Prediction. Genes, 13.","DOI":"10.3390\/genes13081374"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1751-553X.2010.01254.x","article-title":"CD66c expression in B-cell acute lymphoblastic leukemia: Strength and weakness","volume":"33","author":"Guillaume","year":"2011","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3324\/haematol.2008.000299","article-title":"Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia","volume":"94","author":"Djokic","year":"2009","journal-title":"Haematologica"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.3109\/10428194.2015.1070153","article-title":"The application of CD73 in minimal residual disease monitoring using flow cytometry in B-cell acute lymphoblastic leukemia","volume":"57","author":"Wang","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/ijlh.13456","article-title":"Expression of CD304\/neuropilin-1 in adult b-cell lymphoblastic leukemia\/lymphoma and its utility for the measurable residual disease assessment","volume":"43","author":"Chatterjee","year":"2021","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/cyto.b.21866","article-title":"CD304\/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia","volume":"98","author":"Gudapati","year":"2020","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/bjh.14685","article-title":"Understanding the reconstitution of the B-cell compartment in bone marrow and blood after treatment for B-cell precursor acute lymphoblastic leukemia","volume":"178","author":"Theunissen","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/ijlh.14348","article-title":"Immunophenotypic features of early haematopoietic and leukaemia stem cells","volume":"46","author":"Reuvekamp","year":"2024","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Sadovnik, I., Herrmann, H., Blatt, K., Eisenwort, G., Mueller, N., Stefanzl, G., Hoermann, G., Herndlhofer, S., Bauer, K., and Peter, B. (2016). Evaluation of Cell Surface Markers and Targets in Leukemic Stem Cells (LSC) Reveals Distinct Expression Profiles, Unique Drug Effects, and Specific Checkpoint Regulation in AML LSC and CML LSC. Blood, 128.","DOI":"10.1182\/blood.V128.22.4234.4234"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Silva, W., and Rego, E. (2023). How to Manage Philadelphia-Positive Acute Lymphoblastic Leukemia in Resource-Constrained Settings. Cancers, 15.","DOI":"10.3390\/cancers15245783"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/sj.leu.2403664","article-title":"Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: Patterns of residual leukemia and prognostic factors for cytogenetic relapse","volume":"19","author":"Marin","year":"2005","journal-title":"Leukemia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes","volume":"26","author":"Lhermitte","year":"2012","journal-title":"Leukemia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/blood.V82.6.1929.1929","article-title":"Competitive Polymerase Chain Reaction to Estimate the Number of BCR-ABL Transcripts in Chronic Myeloid Leukemia Patients After Bone Marrow Transplantation","volume":"82","author":"Cross","year":"1993","journal-title":"Blood"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/5\/2116\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:43:42Z","timestamp":1760028222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/5\/2116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["ijms26052116"],"URL":"https:\/\/doi.org\/10.3390\/ijms26052116","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]}}}